In Vitro Diagnostics Market to Reach US$ 170.10 Bn by 2031, Growing at 7.7% CAGR: New Report by Wissen Research

Wissen Research forecasts the global in-vitro diagnostics market to grow from $117.39 billion in 2026 to $170.10 billion by 2031, a 7.7% CAGR, with molecular diagnostics expanding at a sector-leading 14.7% CAGR. Reagents and kits represented about 70% of 2025 market revenue, while North America held a 39% share and Asia-Pacific is expected to grow fastest. Recent strategic activity—including Danaher’s $9.9 billion acquisition of Masimo’s patient-monitoring business and Roche’s planned PathAI acquisition—highlights major players’ push into AI-enabled diagnostics and digital pathology.

Analysis

This is not a new earnings catalyst; it is a vendor-sponsored market forecast and should not justify a broad diagnostics rerating. The investable implication is narrower: platform vendors with high installed-base utilization and proprietary consumables should convert incremental test volume into gross-margin expansion, while instrument-heavy suppliers face longer sales cycles, tender pressure, and greater exposure to hospital capital-budget constraints. DHR, ABT and QGEN are better positioned for recurring assay/sample-prep pull-through than BIO or BDX, where the diagnostic contribution and operating leverage are less direct.

The more consequential competitive shift is that AI/pathology and decentralized testing can redistribute economics away from stand-alone instruments toward workflow ownership: assay menu, informatics, sample preparation and service contracts. DHR's monitoring acquisition could create hospital-account cross-selling, but the purchase price raises integration and deleveraging hurdles; unless it produces measurable diagnostics revenue synergies, the market may treat it as a lower-multiple monitoring asset rather than a diagnostics multiple-expander. TMO and ILMN retain exposure to molecular growth, but neither should be assumed to capture routine clinical volume without reimbursement expansion and evidence that labs adopt their workflows rather than lower-cost PCR alternatives.

Over the next 1-3 months, watch quarterly organic diagnostics growth, consumables growth versus instrument growth, Asia-Pacific order trends, and reimbursement decisions for molecular/companion tests. A sustained mix shift toward reagents and software would support margins and multiples over 6-18 months; conversely, hospital capex deferrals, reimbursement cuts, or slower infectious-disease testing would expose the gap between secular-growth narratives and near-term revenue. The contrarian view is that molecular growth is already well understood: the underappreciated risk is price compression as multiplex panels proliferate, especially where payors reimburse a clinical episode rather than each analyte.

Key Decisions for Investors

• No broad sector trade on this release. Treat it as a watch item; require independently reported acceleration in consumables and molecular diagnostics organic growth before adding exposure.
• Prefer a 6-12 month long DHR / short BDX pair, sized modestly: DHR has greater potential to monetize workflow and consumables, while BDX has more hospital-capex and lower-growth specimen-management exposure. Exit if DHR Diagnostics organic growth fails to exceed BDX's relevant diagnostics growth for two consecutive quarters or acquisition-related leverage/synergy guidance deteriorates.
• Maintain ABT as the lower-beta diagnostics expression into the next two earnings cycles, but add only after evidence that core diagnostics growth—not temporary respiratory testing—drives upside. Thesis is falsified by reagent-volume deceleration or a material margin-guidance cut.
• Keep ILMN and TMO on a reimbursement-and-adoption alert rather than buying the molecular theme outright. Initiate only if clinical sequencing utilization and consumables growth accelerate simultaneously; absent that confirmation, PCR and targeted-panel substitution can cap incremental returns despite favorable long-term market growth.
• For SHL, monitor capillary-menu adoption and reagent pull-through over the next 2-4 quarters. A positive instrument-placement update without recurring revenue disclosure is not sufficient for a position, since decentralized testing can dilute economics if it shifts volume from higher-throughput central labs.